Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer

Abstract

Oncolytic virotherapy is an emerging cancer immunotherapy that combines selective tumor cell lysis with activation of systemic antitumor immunity. Various DNA- and RNA-based oncolytic viruses (OVs) have demonstrated favorable safety profiles and therapeutic activity across different malignancies. Despite these advancements, clinical efficacy remains inconsistent because of several biological barriers, including rapid immune clearance, insufficient tumor targeting, limited intratumoral spread, and the immunosuppressive tumor microenvironment (TME). In this review, we examine the key mechanisms of OV infection, tumor selectivity, and virus-induced antitumor immune responses. It also explores the factors that limit therapeutic efficacy, particularly host antiviral immunity, structural barriers within solid tumors, and the immunosuppressive networks in the TME. To address these challenges, a range of strategies have been developed, with a focus on optimizing viral delivery. Current approaches, such as cell-based carriers, extracellular vesicle-mediated transport, and nanomaterial-assisted delivery systems, aim to enhance tumor targeting, protect viral integrity, and improve intratumoral distribution. Additionally, combination therapies designed to enhance antitumor immunity and reshape the TME are outlined, including immune checkpoint blockade, chemoradiotherapy, and metabolic modulation. Collectively, these advancements transform OVs from standalone cytolytic agents into adaptable immunotherapeutic platforms, with their effectiveness determined by the delivery method, microenvironmental conditions, and therapeutic integration.

Keywords

antitumor therapy / combination treatment strategies / immunotherapy / oncolytic viruses / viral delivery

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[2] Y. Zhang and Z. Zhang, “The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-infiltrating Immune Cells and Their Therapeutic Implications,” Cell Mol Immunol 17, no. 8 (2020): 807–821.

[3] R. Rui, L. Zhou, and S. He, “Cancer Immunotherapies: Advances and Bottlenecks,” Frontiers in Immunology 14 (2023): 1212476.

[4] E. Appleton, E. A. Chiocca, G. Ungerechts, A. Melcher, and R. Vile, “Oncolytic Viruses as Anticancer Agents: Clinical Progress and Remaining Challenges,” Lancet 406, no. 10509 (2025): 1295–1312.

[5] J. Xu, Y. Fang, K. Chen, et al., “Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer,” Clinical Cancer Research 28, no. 16 (2022): 3590–3602.

[6] J. A. Chesney, A. Ribas, G. V. Long, et al., “Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma,” Journal of Clinical Oncology 41, no. 3 (2023): 528–540.

[7] D. Lin, Y. Shen, and T. Liang, “Oncolytic Virotherapy: Basic Principles, Recent Advances and Future Directions,” Signal Transduct Target Ther 8, no. 1 (2023): 156.

[8] Z. S. Singer, J. Pabón, H. Huang, et al., “Engineered Bacteria Launch and Control an Oncolytic Virus,” Nat Biomed Eng (2025).

[9] L. Guo, C. Hu, Y. Liu, et al., “Directed Natural Evolution Generates a next-generation Oncolytic Virus With a High Potency and Safety Profile,” Nature Communications 14, no. 1 (2023): 3410.

[10] S. Z. Shalhout, D. M. Miller, K. S. Emerick, and H. L. Kaufman, “Therapy With Oncolytic Viruses: Progress and Challenges,” Nature Reviews Clinical oncology 20, no. 3 (2023): 160–177.

[11] R. Ma, Z. Li, E. A. Chiocca, M. A. Caligiuri, and J. Yu, “The Emerging Field of Oncolytic Virus-based Cancer Immunotherapy,” Trends in Cancer 9, no. 2 (2023): 122–139.

[12] C. Chen, J. Cillis, S. Deshpande, et al., “Oncolytic Virotherapy in Solid Tumors: A Current Review,” Biodrugs 39, no. 6 (2025): 857–876.

[13] C. Catacalos-Goad, C. Johnstone, and V. Z. Grdzelishvili, “Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends,” Current Oncology 32, no. 11 (2025): 627.

[14] T. Delaunay, C. Achard, N. Boisgerault, et al., “Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus,” Journal of Thoracic Oncology 15, no. 5 (2020): 827–842.

[15] N. Sharifi, A. Emamie, N. Rafiee, et al., “Reovirus Oncolysis and the next Frontiers for this Unique Oncoviral Immunotherapy,” Seminars in Immunology 80 (2025): 101995.

[16] S. Yuan, J. Wang, D. Zhu, et al., “Cryo-EM Structure of a Herpesvirus Capsid at 3.1 Å,” Science 360, no. 6384 (2018): eaao7283.

[17] R. Dos Santos Natividade, M. Koehler, and P. Gomes, “Deciphering Molecular Mechanisms Stabilizing the Reovirus-binding Complex,” PNAS 120, no. 21 (2023): e2220741120.

[18] M. Pérez-Illana, M. Martínez, G. N. Condezo, et al., “Cryo-EM Structure of Enteric adenovirus HAdV-F41 Highlights Structural Variations Among human Adenoviruses,” Science Advances 7, no. 9 (2021): eabd9421.

[19] A. T. Baker, A. Greenshields-Watson, L. Coughlan, et al., “Diversity Within the adenovirus fiber Knob Hypervariable Loops Influences Primary Receptor Interactions,” Nature Communications 10, no. 1 (2019): 741.

[20] M. Zhou, W. Chen, D. Zhang, et al., “Identification and Characterization of a Novel human adenovirus Type HAdV-D116,” Frontiers in Microbiology 16 (2025): 1566316.

[21] B. D. Persson, L. John, K. Rafie, et al., “Human Species D adenovirus Hexon Capsid Protein Mediates Cell Entry Through a Direct Interaction With CD46,” PNAS 118, no. 3 (2021): e2020732118.

[22] M. M. Ahmed, O. J. Okesanya, B. M. Ukoaka, A. M. Ibrahim, and D. E. Lucero-Prisno, “Vesicular Stomatitis Virus: Insights Into Pathogenesis, Immune Evasion, and Technological Innovations in Oncolytic and Vaccine Development,” Viruses 16, no. 12 (2024): 1933.

[23] S. Akash, M. R. Islam, and M. M. Rahman, “Measles Virus Outbreak: A New Concern for Public Health, Pathogenesis, Diagnosis, Genomic Features, and Treatment Criteria—correspondence,” Int J Surg 109, no. 2 (2023): 201–203.

[24] Y. Lv, S. Zhou, S. Gao, and H. Deng, “Remodeling of Host Membranes During Herpesvirus Assembly and Egress,” Protein Cell 10, no. 5 (2019): 315–326.

[25] M. Koehler, P. Aravamudhan, C. Guzman-Cardozo, et al., “Glycan-mediated Enhancement of Reovirus Receptor Binding,” Nature Communications 10, no. 1 (2019): 4460.

[26] M. Muñoz-Alía, R. A. Nace, L. Zhang, and S. J. Russell, “Serotypic Evolution of measles Virus Is Constrained by Multiple co-dominant B Cell Epitopes on Its Surface Glycoproteins,” Cell Rep Med 2, no. 4 (2021): 100225.

[27] Y. Dai, M. Idorn, M. C. Serrero, et al., “TMEFF1 is a Neuron-specific Restriction Factor for herpes Simplex Virus,” Nature 632, no. 8024 (2024): 383–389.

[28] L. Zhong, W. Zhang, C. Krummenacher, et al., “Targeting Herpesvirus Entry Complex and Fusogen Glycoproteins With Prophylactic and Therapeutic Agents,” Trends in Microbiology 31, no. 8 (2023): 788–804.

[29] Q. F. Lin, C. X. L. Wong, H. E. Eaton, X. Pang, and M. Shmulevitz, “Reovirus Genomic Diversity Confers Plasticity for Protease Utility During Adaptation to Intracellular Uncoating,” Journal of Virology 97, no. 10 (2023): e0082823.

[30] A. T. Abad, A. J. McNamara, and P. Danthi, “Proteasome Activity Is Required for Reovirus Entry Into Cells,” Journal of Virology 97, no. 10 (2023): e0134823.

[31] M. Minoves, M. Ouldali, L. Belot, et al., “Structures of Vesicular Stomatitis Virus Glycoprotein G Alone and Bound to a Neutralizing Antibody,” Plos Pathogens 21, no. 10 (2025): e1013589.

[32] J. M. Ramirez, A. C. Calderon-Zavala, A. Balaram, and E. E. Heldwein, “In Vitro Reconstitution of herpes Simplex Virus 1 Fusion Identifies Low pH as a Fusion co-trigger,” MBio 14, no. 6 (2023): e0208723.

[33] C. A. Doyle, G. W. Busey, W. H. Iobst, et al., “Endosomal Fusion of pH-dependent Enveloped Viruses Requires Ion Channel TRPM7,” Nature Communications 15, no. 1 (2024): 8479.

[34] B. Lucic, I. J. de Castro, and M. Lusic, “Viruses in the Nucleus,” Cold Spring Harbor Perspectives in Biology 13, no. 8 (2021): a039446.

[35] M. D. Greseth and P. Traktman, “The Life Cycle of the Vaccinia Virus Genome,” Annu Rev Virol 9, no. 1 (2022): 239–259.

[36] L. Z. Kong, S. M. Kim, C. Wang, et al., “Understanding Nucleic Acid Sensing and Its Therapeutic Applications,” Experimental & Molecular Medicine 55, no. 11 (2023): 2320–2331.

[37] D. Boehmer and I. Zanoni, “Interferons in Health and Disease,” Cell 188, no. 17 (2025): 4480–4504.

[38] S. Dvorkin, S. Cambier, H. E. Volkman, and D. B. Stetson, “New Frontiers in the cGAS-STING Intracellular DNA-sensing Pathway,” Immunity 57, no. 4 (2024): 718–730.

[39] A. Alwithenani, P. Hengswat, and E. A. Chiocca, “Oncolytic Viruses as Cancer Therapeutics: From Mechanistic Insights to Clinical Translation,” Molecular Therapy 33, no. 5 (2025): 2217–2228.

[40] K. Geoffroy and M. C. Bourgeois-Daigneault, “The Pros and Cons of Interferons for Oncolytic Virotherapy,” Cytokine & Growth Factor Reviews 56 (2020): 49–58.

[41] F. J. Kohlhapp and H. L. Kaufman, “Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy,” Clinical Cancer Research 22, no. 5 (2016): 1048–1054.

[42] M. E. Bahar, H. J. Kim, and D. R. Kim, “Targeting the RAS/RAF/MAPK Pathway for Cancer Therapy: From Mechanism to Clinical Studies,” Signal Transduct Target Ther 8, no. 1 (2023): 455.

[43] M. Thai, N. A. Graham, D. Braas, et al., “Adenovirus E4ORF1-induced MYC Activation Promotes Host Cell Anabolic Glucose Metabolism and Virus Replication,” Cell metabolism 19, no. 4 (2014): 694–701.

[44] Z. Zhu, A. J. R. McGray, W. Jiang, B. Lu, P. Kalinski, and Z. S. Guo, “Improving Cancer Immunotherapy by Rationally Combining Oncolytic Virus With Modulators Targeting Key Signaling Pathways,” Molecular cancer 21, no. 1 (2022): 196.

[45] Y. Kato, N. Rice, M. Pokrass, et al., “Nonclinical Characterization of ICVB-1042 as a Selective Oncolytic adenovirus for Solid Tumor Treatment,” Communications Biology 7, no. 1 (2024): 1132.

[46] V. Krenn, C. Bosone, T. R. Burkard, et al., “Organoid Modeling of Zika and herpes simplex virus 1 Infections Reveals Virus-specific Responses Leading to Microcephaly,” Cell Stem Cell 28, no. 8 (2021): 1362–1379.e7.

[47] H. Kang, Y. J. Ga, S. H. Kim, et al., “Small Interfering RNA (siRNA)-based Therapeutic Applications Against Viruses: Principles, Potential, and Challenges,” Journal of Biomedical Science 30, no. 1 (2023): 88.

[48] V. Roulstone, J. Kyula-Currie, J. Wright, et al., “Palbociclib and dsRNA Sensor co-operate to Enhance Anti-cancer Effects Through ER Stress and Modulation of Immune Evasion,” Nature Communications 16, no. 1 (2025): 4855.

[49] J. J. Rojas, P. Sampath, B. Bonilla, et al., “Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies,” Cell reports 15, no. 2 (2016): 264–273.

[50] Y. Jiang, H. Zhang, J. Wang, et al., “Exploiting RIG-I-Like Receptor Pathway for Cancer Immunotherapy,” Journal of hematology & oncology 16, no. 1 (2023): 8.

[51] T. Suzuki and H. Uchida, “Induction of Necroptosis in Multinucleated Giant Cells Induced by Conditionally Replicating Syncytial oHSV in co-cultures of Cancer Cells and Non-cancerous Cells,” Mol Ther Oncol 32, no. 2 (2024): 200803.

[52] J. M. White, A. E. Ward, L. Odongo, and L. K. Tamm, “Viral Membrane Fusion: A Dance between Proteins and Lipids,” Annu Rev Virol 10, no. 1 (2023): 139–161.

[53] T. Alain, T. S. Kim, X. Lun, et al., “Proteolytic Disassembly Is a Critical Determinant for Reovirus Oncolysis,” Molecular Therapy 15, no. 8 (2007): 1512–1521.

[54] Y. Wang, C. Liu, J. Pang, Z. Li, J. Zhang, and L. Dong, “The Extra-Tumoral Vaccine Effects of Apoptotic Bodies in the Advancement of Cancer Treatment,” Small 21, no. 9 (2025): e2410503.

[55] D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele, “Immunogenic Cell Death and DAMPs in Cancer Therapy,” Nature Reviews Cancer 12, no. 12 (2012): 860–875.

[56] J. Svensson-Arvelund, S. Cuadrado-Castano, G. Pantsulaia, et al., “Expanding Cross-presenting Dendritic Cells Enhances Oncolytic Virotherapy and Is Critical for Long-term Anti-tumor Immunity,” Nature Communications 13, no. 1 (2022): 7149.

[57] M. Li, Y. Zhang, L. Zong, et al., “An Oncolytic vaccinia Virus Expressing Anti-CD47 Nanobody Exerts Enhanced Antitumor Activity by Mediating Innate and Adaptive Immune Cell Infiltration and Activation in the Lymphoma Tumor Microenvironment,” Haematologica 110, no. 9 (2025): 2113–2128.

[58] M. Yi, T. Li, M. Niu, et al., “Targeting Cytokine and Chemokine Signaling Pathways for Cancer Therapy,” Signal Transduct Target Ther 9, no. 1 (2024): 176.

[59] R. Tokunaga, W. Zhang, M. Naseem, et al., “CXCL9, CXCL10, CXCL11/CXCR3 axis for Immune Activation—A Target for Novel Cancer Therapy,” Cancer Treatment Reviews 63 (2018): 40–47.

[60] Q. Zhang and F. Liu, “Advances and Potential Pitfalls of Oncolytic Viruses Expressing Immunomodulatory Transgene Therapy for Malignant Gliomas,” Cell death & disease 11, no. 6 (2020): 485.

[61] D. B. Rivadeneira, K. DePeaux, Y. Wang, et al., “Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance,” Immunity 51, no. 3 (2019): 548–560.e4.

[62] Y. Xia, D. Li, K. Yang, and X. Ou, “Systemic Delivery Strategies for Oncolytic Viruses: Advancing Targeted and Efficient Tumor Therapy,” International Journal of Molecular Sciences 26, no. 14 (2025): 6900.

[63] Z. Peng, M. Kalim, and Y. Lu, “Improving Systemic Delivery of Oncolytic Virus by Cellular Carriers,” Cancer Biol Med 21, no. 12 (2025): 1104–1119.

[64] S. Singh, D. Dey, D. Barik, et al., “Glioblastoma at the Crossroads: Current Understanding and Future Therapeutic Horizons,” Signal Transduct Target Ther 10, no. 1 (2025): 213.

[65] Y. Liu, F. Zhou, H. Ali, J. D. Lathia, and P. Chen, “Immunotherapy for Glioblastoma: Current state, Challenges, and Future Perspectives,” Cell Mol Immunol 21, no. 12 (2024): 1354–1375.

[66] M. Hammad, Y. R. Cornejo, J. Batalla-Covello, et al., “Neural Stem Cells Improve the Delivery of Oncolytic Chimeric Orthopoxvirus in a Metastatic Ovarian Cancer Model,” Mol Ther Oncolytics 18 (2020): 326–334.

[67] T. M. Liu, W. Tew, Z. Yang, et al., “Understanding the Molecular Basis of Mesenchymal Stem Cell Stemness: Implications for Clinical Applications,” Cell death & disease 16, no. 1 (2025): 778.

[68] B. G. Rash, K. N. Ramdas, N. Agafonova, et al., “Allogeneic Mesenchymal Stem Cell Therapy With laromestrocel in Mild Alzheimer's Disease: A Randomized Controlled Phase 2a Trial,” Nature Medicine 31, no. 4 (2025): 1257–1266.

[69] N. Song, M. Scholtemeijer, and K. Shah, “Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential,” Trends in Pharmacological Sciences 41, no. 9 (2020): 653–664.

[70] R. Antoon, N. Overdevest, A. H. Saleh, and A. Keating, “Mesenchymal Stromal Cells as Cancer Promoters,” Oncogene 43, no. 49 (2024): 3545–3555.

[71] A. E. Karnoub, A. B. Dash, A. P. Vo, et al., “Mesenchymal Stem Cells Within Tumour Stroma Promote Breast Cancer Metastasis,” Nature 449, no. 7162 (2007): 557–563.

[72] J. Tang, Y. Chen, C. Wang, et al., “The Role of Mesenchymal Stem Cells in Cancer and Prospects for Their Use in Cancer Therapeutics,” MedComm 2020 5, no. 8 (2024): e663.

[73] Y. Fu, M. Zhang, B. Sui, et al., “Mesenchymal Stem Cell-derived Apoptotic Vesicles Ameliorate Impaired Ovarian Folliculogenesis in Polycystic Ovary Syndrome and Ovarian Aging by Targeting WNT Signaling,” Theranostics 14, no. 8 (2024): 3385–3403.

[74] T. Lan, M. Luo, and X. Wei, “Mesenchymal Stem/Stromal Cells in Cancer Therapy,” Journal of hematology & oncology 14, no. 1 (2021): 195.

[75] Z. Zhang, N. Yang, L. Xu, et al., “Systemic Delivery of Oncolytic herpes Virus Using CAR-T Cells Enhances Targeting of Antitumor Immuno-virotherapy,” Cancer Immunology, Immunotherapy 73, no. 9 (2024): 173.

[76] L. Evgin, T. Kottke, J. Tonne, et al., “Oncolytic Virus-mediated Expansion of Dual-specific CAR T Cells Improves Efficacy Against Solid Tumors in Mice,” Science Translational Medicine 14, no. 640 (2022): eabn2231.

[77] N. Watanabe, M. K. McKenna, A. Rosewell Shaw, and M. Suzuki, “Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment,” Molecular Therapy 29, no. 2 (2021): 505–520.

[78] X. Zhang, L. Zhu, H. Zhang, S. Chen, and Y. Xiao, “CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges,” Frontiers in immunology 13 (2022): 927153.

[79] L. Amini, S. K. Silbert, S. L. Maude, et al., “Preparing for CAR T Cell Therapy: Patient Selection, Bridging Therapies and Lymphodepletion,” Nature reviews Clinical oncology 19, no. 5 (2022): 342–355.

[80] A. Gottschlich, M. Thomas, R. Grünmeier, et al., “Single-cell Transcriptomic Atlas-guided Development of CAR-T Cells for the Treatment of Acute Myeloid Leukemia,” Nature Biotechnology 41, no. 11 (2023): 1618–1632.

[81] R. C. Sterner and R. M. Sterner, “CAR-T Cell Therapy: Current Limitations and Potential Strategies,” Blood cancer journal 11, no. 4 (2021): 69.

[82] Y. Sun, J. Liu, D. Zhan, et al., “Depletion of Tregs From CD4(+) CAR-T Cells Enhances the Tumoricidal Effect of CD8(+) CAR-T Cells in Anti-CD19 CAR-T Therapy,” Febs Journal 292, no. 8 (2025): 1904–1919.

[83] A. R. Sánchez-Paulete, J. Mateus-Tique, G. Mollaoglu, et al., “Targeting Macrophages With CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity,” Cancer immunology research 10, no. 11 (2022): 1354–1369.

[84] Y. Wang, D. L. Drum, R. Sun, et al., “Stressed Target Cancer Cells Drive Nongenetic Reprogramming of CAR T Cells and Solid Tumor Microenvironment,” Nature Communications 14, no. 1 (2023): 5727.

[85] Y. Wang, J. W. Cho, G. Kastrunes, et al., “Immune-restoring CAR-T Cells Display Antitumor Activity and Reverse Immunosuppressive TME in a Humanized ccRCC Mouse Model,” Iscience 27, no. 2 (2024): 108879.

[86] F. Xing, X. Wang, Z. Li, et al., “Specific Loading of Oncolytic VSV on CAR Enhances CAR-T Cell Signaling and Antitumor Activity,” Journal of Experimental Medicine 222, no. 11 (2025): e20241851.

[87] G. Wang, Z. Zhang, K. Zhong, et al., “CXCL11-armed Oncolytic Adenoviruses Enhance CAR-T Cell Therapeutic Efficacy and Reprogram Tumor Microenvironment in Glioblastoma,” Molecular Therapy 31, no. 1 (2023): 134–153.

[88] M. K. McKenna, A. Englisch, B. Brenner, et al., “Mesenchymal Stromal Cell Delivery of Oncolytic Immunotherapy Improves CAR-T Cell Antitumor Activity,” Molecular Therapy 29, no. 5 (2021): 1808–1820.

[89] M. Vermeer, C. Sparano, N. Coianiz, et al., “Tissue Localization of Natural Killer Cells Dictates Surveillance of Lung Metastasis,” Nature Communications 16, no. 1 (2025): 9464.

[90] X. Liu, J. Song, H. Zhang, et al., “Immune Checkpoint HLA-E:CD94-NKG2A Mediates Evasion of Circulating Tumor Cells From NK Cell Surveillance,” Cancer Cell 41, no. 2 (2023): 272–287.e9.

[91] Y. Li, Z. Li, Y. Tang, et al., “Unlocking the Therapeutic Potential of the NKG2A-HLA-E Immune Checkpoint Pathway in T Cells and NK Cells for Cancer Immunotherapy,” Journal for ImmunoTherapy of Cancer 12, no. 10 (2024): e009934.

[92] L. M. E. Müller, G. Migneco, G. B. Scott, et al., “Reovirus-induced Cell-mediated Immunity for the Treatment of Multiple Myeloma Within the Resistant Bone Marrow Niche,” Journal for ImmunoTherapy of Cancer 9, no. 3 (2021): e001803.

[93] M. Wantoch, E. B. Wilson, A. P. Droop, et al., “Oncolytic Virus Treatment Differentially Affects the CD56(dim) and CD56(bright) NK Cell Subsets in Vivo and Regulates a Spectrum of human NK Cell Activity,” Immunology 166, no. 1 (2022): 104–120.

[94] A. Yang, X. Wang, and L. Jin, “Human Umbilical Cord Mesenchymal Stem Cell Exosomes Deliver Potent Oncolytic Reovirus to Acute Myeloid Leukemia Cells,” Virology 598 (2024): 110171.

[95] P. Shirmast, M. A. Shahri, A. Brent, A. Idris, and N. A. J. McMillan, “Delivering Therapeutic RNA Into the Brain Using Extracellular Vesicles,” Mol Ther Nucleic Acids 35, no. 4 (2024): 102373.

[96] R. Cecchin, Z. Troyer, K. Witwer, and K. V. Morris, “Extracellular Vesicles: The next Generation in Gene Therapy Delivery,” Molecular Therapy 31, no. 5 (2023): 1225–1230.

[97] Y. K. Kim, Y. Hong, Y. R. Bae, et al., “Advantage of Extracellular Vesicles in Hindering the CD47 Signal for Cancer Immunotherapy,” J Control Release 351 (2022): 727–738.

[98] H. Liu, M. Li, B. Xiang, et al., “An Integrated “Engage & Evasion” Approach for Mononuclear Phagocyte System Escape and Efficient Extracellular Vesicle Therapy,” J Nanobiotechnology 22, no. 1 (2024): 770.

[99] M. T. Roefs, J. Gamauf, B. Kroenigsberger, et al., “Rapid Extracellular Vesicle Surface Decoration With Targeting Moieties Based on a Fluorescein Binding Single Chain Variable Fragment Snorkel,” J Control Release 390 (2025): 114558.

[100] J. Jiang, Y. Lu, J. Chu, et al., “Anti-EGFR ScFv Functionalized Exosomes Delivering LPCAT1 Specific siRNAs for Inhibition of Lung Cancer Brain Metastases,” J Nanobiotechnology 22, no. 1 (2024): 159.

[101] F. Zahednezhad, M. Saadat, H. Valizadeh, P. Zakeri-Milani, and B. Baradaran, “Liposome and Immune System Interplay: Challenges and Potentials,” J Control Release 305 (2019): 194–209.

[102] X. Cheng, J. Gao, Y. Ding, et al., “Multi-Functional Liposome: A Powerful Theranostic Nano-Platform Enhancing Photodynamic Therapy,” Adv Sci (Weinh) 8, no. 16 (2021): e2100876.

[103] S. Shah, V. Dhawan, R. Holm, M. S. Nagarsenker, and Y. Perrie, “Liposomes: Advancements and Innovation in the Manufacturing Process,” Advanced Drug Delivery Reviews 154-155 (2020): 102–122.

[104] M. S. Hanwei Huang, M. Liu, S. Pan, et al., “Full Encapsulation of Oncolytic Virus Using Hybrid Erythroctye-liposome Membranes for Augmented Anti-refractory Tumor Effectiveness,” Nano Today 47 (2022): 101671.

[105] E. L. Dane, A. Belessiotis-Richards, C. Backlund, et al., “STING Agonist Delivery by Tumour-penetrating PEG-lipid Nanodiscs Primes Robust Anticancer Immunity,” Nature Materials 21, no. 6 (2022): 710–720.

[106] A. M. Sofias, Y. C. Toner, A. E. Meerwaldt, et al., “Tumor Targeting by α(v)β(3)-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking,” ACS Nano 14, no. 7 (2020): 7832–7846.

[107] H. Wang, R. Gou, W. Li, et al., “Targeting Delivery of Dexamethasone to Inflamed Joints by Albumin-Binding Peptide Modified Liposomes for Rheumatoid Arthritis Therapy,” Int J Nanomedicine 20 (2025): 3789–3802.

[108] Y. Li, R. Shao, C. A. Ostertag-Hill, M. Torre, R. Yan, and D. S. Kohane, “Methyl-Branched Liposomes as a Depot for Sustained Drug Delivery,” Nano Letters 23, no. 20 (2023): 9250–9256.

[109] S. Fu, L. Chang, S. Liu, et al., “Temperature Sensitive Liposome Based Cancer Nanomedicine Enables Tumour Lymph Node Immune Microenvironment Remodelling,” Nature Communications 14, no. 1 (2023): 2248.

[110] A. S. Piotrowski-Daspit, L. G. Bracaglia, D. A. Eaton, et al., “Enhancing in Vivo Cell and Tissue Targeting by Modulation of Polymer Nanoparticles and Macrophage Decoys,” Nature Communications 15, no. 1 (2024): 4247.

[111] T. G. Floyd, P. Gurnani, and J. Y. Rho, “Characterisation of Polymeric Nanoparticles for Drug Delivery,” Nanoscale 17, no. 13 (2025): 7738–7752.

[112] H. Tang, H. Wang, Z. Gan, Z. Ding, and Q. Yu, “Engineering the Hydrophilic-Hydrophobic Interface of Polymeric Micelles by Cationic Blocks for Enhanced Chemotherapy,” ACS Appl Mater Interfaces 16, no. 50 (2024): 69011–69027.

[113] Z. T. Bennett, G. Huang, M. T. Dellinger, B. D. Sumer, and J. Gao, “Stepwise Ultra-pH-Sensitive Micelles Overcome a pK(a) Barrier for Systemic Lymph Node Delivery,” ACS Nano 18, no. 26 (2024): 16632–16647.

[114] T. L. Sheehy, A. J. Kwiatkowski, K. Arora, et al., “STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy,” ACS Cent Sci 10, no. 9 (2024): 1765–1781.

[115] Z. Zhang, X. Xu, J. Du, et al., “Redox-responsive Polymer Micelles co-encapsulating Immune Checkpoint Inhibitors and Chemotherapeutic Agents for Glioblastoma Therapy,” Nature Communications 15, no. 1 (2024): 1118.

[116] S. Yamada, E. Sasaki, H. Ohno, and K. Hanaoka, “Heat-guided Drug Delivery via Thermally Induced Crosslinking of Polymeric Micelles,” Commun Chem 7, no. 1 (2024): 287.

[117] L. Y. C. Madruga and M. J. Kipper, “Expanding the Repertoire of Electrospinning: New and Emerging Biopolymers, Techniques, and Applications,” Adv Healthc Mater 11, no. 4 (2022): e2101979.

[118] N. Kanaya, Y. Kitamura, M. Lopez Vazquez, et al., “Gene-edited and -engineered Stem Cell Platform Drives Immunotherapy for Brain Metastatic Melanomas,” Science Translational Medicine 15, no. 698 (2023): eade8732.

[119] H. Chai, H. Xu, S. Jiang, et al., “Neural Stem Cell-delivered Oncolytic Virus via Intracerebroventricular Administration Enhances Glioblastoma Therapy and Immune Modulation,” Journal for ImmunoTherapy of Cancer 13, no. 10 (2025): e012934.

[120] J. Fares, A. U. Ahmed, I. V. Ulasov, et al., “Neural Stem Cell Delivery of an Oncolytic adenovirus in Newly Diagnosed Malignant Glioma: A First-in-human, Phase 1, Dose-escalation Trial,” The Lancet Oncology 22, no. 8 (2021): 1103–1114.

[121] Y. Cornejo, M. Li, T. H. Dellinger, et al., “NSCs Are Permissive to Oncolytic Myxoma Virus and Provide a Delivery Method for Targeted Ovarian Cancer Therapy,” Oncotarget 11, no. 51 (2020): 4693–4698.

[122] R. Moreno, “Mesenchymal Stem Cells and Oncolytic Viruses: Joining Forces Against Cancer,” Journal for ImmunoTherapy of Cancer 9, no. 2 (2021): e001684.

[123] W. Du, I. Seah, O. Bougazzoul, et al., “Stem Cell-released Oncolytic herpes Simplex Virus Has Therapeutic Efficacy in Brain Metastatic Melanomas,” PNAS 114, no. 30 (2017): E6157–e6165.

[124] L. Franco-Luzón, Á. González-Murillo, C. Alcántara-Sánchez, et al., “Systemic Oncolytic adenovirus Delivered in Mesenchymal Carrier Cells Modulate Tumor Infiltrating Immune Cells and Tumor Microenvironment in Mice With Neuroblastoma,” Oncotarget 11, no. 4 (2020): 347–361.

[125] E. Rincón, T. Cejalvo, D. Kanojia, et al., “Mesenchymal Stem Cell Carriers Enhance Antitumor Efficacy of Oncolytic Adenoviruses in an Immunocompetent Mouse Model,” Oncotarget 8, no. 28 (2017): 45415–45431.

[126] R. Moreno, C. A. Fajardo, M. Farrera-Sal, et al., “Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination With Peripheral Blood Mononuclear Cells,” Molecular Cancer Therapeutics 18, no. 1 (2019): 127–138.

[127] H. T. Ong, M. J. Federspiel, C. M. Guo, et al., “Systemically Delivered measles Virus-infected Mesenchymal Stem Cells Can Evade Host Immunity to Inhibit Liver Cancer Growth,” Journal of Hepatology 59, no. 5 (2013): 999–1006.

[128] A. Castleton, A. Dey, B. Beaton, et al., “Human Mesenchymal Stromal Cells Deliver Systemic Oncolytic measles Virus to Treat Acute Lymphoblastic Leukemia in the Presence of Humoral Immunity,” Blood 123, no. 9 (2014): 1327–1335.

[129] S. M. Seyed-Khorrami, H. Soleimanjahi, S. Soudi, and A. Habibian, “MSCs Loaded With Oncolytic Reovirus: Migration and in Vivo Virus Delivery Potential for Evaluating Anti-cancer Effect in Tumor-bearing C57BL/6 Mice,” Cancer cell international 21, no. 1 (2021): 244.

[130] X. Wang, Y. Yang, N. Wang, et al., “Mesenchymal Stem Cell Carriers Enhance Antitumor Efficacy Induced by Oncolytic Reovirus in Acute Myeloid Leukemia,” International Immunopharmacology 94 (2021): 107437.

[131] A. R. Yoon, J. Hong, Y. Li, et al., “Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma,” Cancer Research 79, no. 17 (2019): 4503–4514.

[132] A. Kaczorowski, K. Hammer, L. Liu, et al., “Delivery of Improved Oncolytic Adenoviruses by Mesenchymal Stromal Cells for Elimination of Tumorigenic Pancreatic Cancer Cells,” Oncotarget 7, no. 8 (2016): 9046–9059.

[133] K. Hammer, A. Kazcorowski, L. Liu, et al., “Engineered Adenoviruses Combine Enhanced Oncolysis With Improved Virus Production by Mesenchymal Stromal Carrier Cells,” International Journal of Cancer 137, no. 4 (2015): 978–990.

[134] L. Zhong, L. Gan, B. Wang, et al., “Hyperacute Rejection-engineered Oncolytic Virus for Interventional Clinical Trial in Refractory Cancer Patients,” Cell 188, no. 4 (2025): 1119–1136.e23.

[135] K. P. Mueller, J. M. Grenier, and E. W. Weber, “CAR T Cell Persistence in Cancer,” Trends in cancer 11, no. 10 (2025): 1005–1018.

[136] L. Si, D. Wei, J. Pan, R. B. Baleeiro, L. S. Chard Dunmall, and Y. Wang, “CAR-T Cell Exhaustion in Cancer Over the Past Decade: Mitochondrial Metabolism as a Target for Counteraction,” Cancer Letters 639 (2026): 218240.

[137] P. André, C. Denis, C. Soulas, et al., “Anti-NKG2A mAb Is a Checkpoint Inhibitor That Promotes Anti-tumor Immunity by Unleashing both T and NK Cells,” Cell 175, no. 7 (2018): 1731–1743, e13.

[138] B. Salomé, J. P. Sfakianos, D. Ranti, et al., “NKG2A and HLA-E Define an Alternative Immune Checkpoint Axis in Bladder Cancer,” Cancer Cell 40, no. 9 (2022): 1027–1043.e9.

[139] I. Ruiz-Lorente, L. Gimeno, A. López-Abad, et al., “Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated With M. bovis BCG or Other Therapies,” Biomedicines 13, no. 1 (2025): 156.

[140] J. Guillaume, A. Perzolli, and M. Boes, “Strategies to Overcome Low MHC-I Expression in Paediatric and Adult Tumours,” Immunother Adv 4, no. 1 (2024): ltad028.

[141] Z. Shen, X. Meng, J. Rautela, M. Chopin, and N. D. Huntington, “Adjusting the Scope of Natural Killer Cells in Cancer Therapy,” Cell Mol Immunol 22, no. 7 (2025): 699–711.

[142] X. Fang, L. Guo, Z. Xing, et al., “IDO1 can Impair NK Cells Function Against Non-small Cell Lung Cancer by Downregulation of NKG2D Ligand via ADAM10,” Pharmacological Research 177 (2022): 106132.

[143] A. Park, Y. Lee, M. S. Kim, et al., “Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation,” Frontiers in immunology 9 (2018): 1859.

[144] A. Rea, S. Santana-Hernández, J. Villanueva, et al., “Enhancing human NK Cell Antitumor Function by Knocking out SMAD4 to Counteract TGFβ and Activin A Suppression,” Nature Immunology 26, no. 4 (2025): 582–594.

[145] A. Ismael, A. J. Robinette, L. Huric, et al., “CREB1 promotes Expression of Immune Checkpoint HLA-E Leading to Immune Escape in Multiple Myeloma,” Leukemia 38, no. 8 (2024): 1777–1786.

[146] L. Ding, Q. Gao, Z. Xu, et al., “An Inter-Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer,” Adv Sci (Weinh) 9, no. 2 (2022): e2103470.

[147] R. Ma, T. Lu, Z. Li, et al., “An Oncolytic Virus Expressing IL15/IL15Rα Combined With off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma,” Cancer Research 81, no. 13 (2021): 3635–3648.

[148] T. Bexte, N. Albinger, and A. Al Ajami, “CRISPR/Cas9 Editing of NKG2A Improves the Efficacy of Primary CD33-directed Chimeric Antigen Receptor Natural Killer Cells,” Nature Communications 15, no. 1 (2024): 8439.

[149] R. Bhatta, J. Han, Y. Liu, et al., “Injectable Extracellular Vesicle Hydrogels With Tunable Viscoelasticity for Depot Vaccine,” Nature Communications 16, no. 1 (2025): 3781.

[150] N. Shuwari, C. Inoue, I. Ishigami, et al., “Small Extracellular Vesicles Carrying Reovirus, Tumor Antigens, Interferon-β, and Damage-associated Molecular Patterns for Efficient Tumor Treatment,” J Control Release 374 (2024): 89–102.

[151] C. L. Chiang, Y. Ma, Y. C. Hou, et al., “Dual Targeted Extracellular Vesicles Regulate Oncogenic Genes in Advanced Pancreatic Cancer,” Nature Communications 14, no. 1 (2023): 6692.

[152] O. P. B. Wiklander, D. R. Mamand, D. K. Mohammad, et al., “Antibody-displaying Extracellular Vesicles for Targeted Cancer Therapy,” Nat Biomed Eng 8, no. 11 (2024): 1453–1468.

[153] X. Yao, Y. Yoshioka, T. Morishige, et al., “Tumor Vascular Targeted Delivery of Polymer-conjugated adenovirus Vector for Cancer Gene Therapy,” Molecular Therapy 19, no. 9 (2011): 1619–1625.

[154] M. E. Wedge, V. A. Jennings, M. J. F. Crupi, et al., “Virally Programmed Extracellular Vesicles Sensitize Cancer Cells to Oncolytic Virus and Small Molecule Therapy,” Nature Communications 13, no. 1 (2022): 1898.

[155] W. Ban, M. Sun, H. Huang, et al., “Engineered Bacterial Outer Membrane Vesicles Encapsulating Oncolytic Adenoviruses Enhance the Efficacy of Cancer Virotherapy by Augmenting Tumor Cell Autophagy,” Nature Communications 14, no. 1 (2023): 2933.

[156] I. Clares-Pedrero, A. Rocha-Mulero, M. Palma-Cobo, B. Cardeñes, M. Yáñez-Mó, and C. Cabañas, “Molecular Determinants Involved in the Docking and Uptake of Tumor-Derived Extracellular Vesicles: Implications in Cancer,” International Journal of Molecular Sciences 25, no. 6 (2024): 3449.

[157] Y. J. Liu and C. Wang, “A Review of the Regulatory Mechanisms of Extracellular Vesicles-mediated Intercellular Communication,” Cell Communication and Signaling 21, no. 1 (2023): 77.

[158] M. Safarzadeh, N. Saadat, S. Abbasi-Molaei, and M. Rastegari-Pouyani, “Extracellular Vesicles as Missiles for Enhanced Anti-tumor Efficacy of Oncolytic Viruses: From Disseminating Oncolysis and Anti-tumor Immunity to Targeted Delivery,” Cell Communication and Signaling 23, no. 1 (2025): 276.

[159] Y. N. Diep, T. J. Kim, H. Cho, and L. P. Lee, “Nanomedicine for Advanced Cancer Immunotherapy,” J Control Release 351 (2022): 1017–1037.

[160] C. Fang, G. Xiao, T. Wang, et al., “Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy,” Research (Wash D C) 6 (2023): 0108.

[161] M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, and R. Langer, “Engineering Precision Nanoparticles for Drug Delivery,” Nat Rev Drug Discovery 20, no. 2 (2021): 101–124.

[162] J. Soukar, N. A. Peppas, and A. K. Gaharwar, “Organelle-Targeting Nanoparticles,” Adv Sci (Weinh) 12, no. 7 (2025): e2411720.

[163] N. Desai, D. Rana, M. Patel, N. Bajwa, R. Prasad, and L. K. Vora, “Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape,” Small 21, no. 29 (2025): e2502315.

[164] S. Zhu, T. Zhang, L. Zheng, et al., “Combination Strategies to Maximize the Benefits of Cancer Immunotherapy,” Journal of hematology & oncology 14, no. 1 (2021): 156.

[165] P. Dosta, A. M. Cryer, M. Z. Dion, et al., “Investigation of the Enhanced Antitumour Potency of STING Agonist After Conjugation to Polymer Nanoparticles,” Nature Nanotechnology 18, no. 11 (2023): 1351–1363.

[166] H. Sabit, T. M. Pawlik, F. Radwan, et al., “Precision Nanomedicine: Navigating the Tumor Microenvironment for Enhanced Cancer Immunotherapy and Targeted Drug Delivery,” Molecular cancer 24, no. 1 (2025): 160.

[167] J. Y. Han, J. N. La Fiandra, and D. L. DeVoe, “Microfluidic Vortex Focusing for High Throughput Synthesis of Size-tunable Liposomes,” Nature Communications 13, no. 1 (2022): 6997.

[168] Y. Zhao, T. M. D. Le, J. Hong, A. Jiao, A. R. Yoon, and C. O. Yun, “Smart Accumulating Dual-Targeting Lipid Envelopes Equipping Oncolytic Adenovirus for Enhancing Cancer Gene Therapeutic Efficacy,” ACS Nano 18, no. 41 (2024): 27869–27890.

[169] Z. Yang, L. Chen, T. Guo, et al., “Cationic Liposomes Overcome Neutralizing Antibodies and Enhance Reovirus Efficacy in Ovarian Cancer,” Virology 598 (2024): 110196.

[170] J. R. Shah, T. Dong, A. T. Phung, et al., “Liposomal Oncolytic adenovirus as a Neoadjuvant Therapy for Triple-negative Breast Cancer,” Scientific Reports 15, no. 1 (2025): 16737.

[171] M. J. Gouveia, J. Campanhã, F. Barbosa, and N. Vale, “From Mechanism to Medicine: Peptide-Based Approaches for Cancer Diagnosis and Therapy,” Biomolecules 16, no. 1 (2026): 27.

[172] F. Zhang and M. W. King, “Biodegradable Polymers as the Pivotal Player in the Design of Tissue Engineering Scaffolds,” Adv Healthc Mater 9, no. 13 (2020): e1901358.

[173] M. Jurak, A. E. Wiącek, A. Ładniak, K. Przykaza, and K. Szafran, “What Affects the Biocompatibility of Polymers?,” Advances in Colloid and Interface Science 294 (2021): 102451.

[174] Z. Bao, J. Kim, C. Kwok, F. Le Devedec, and C. Allen, “A Dataset on Formulation Parameters and Characteristics of Drug-loaded PLGA Microparticles,” Scientific Data 12, no. 1 (2025): 364.

[175] B. Wan, Q. Bao, and D. Burgess, “Long-acting PLGA Microspheres: Advances in Excipient and Product Analysis Toward Improved Product Understanding,” Advanced Drug Delivery Reviews 198 (2023): 114857.

[176] T. Thambi, J. Hong, A. R. Yoon, and C. O. Yun, “Challenges and Progress Toward Tumor-targeted Therapy by Systemic Delivery of Polymer-complexed Oncolytic Adenoviruses,” Cancer Gene Therapy 29, no. 10 (2022): 1321–1331.

[177] K. D. Fisher, Y. Stallwood, N. K. Green, K. Ulbrich, V. Mautner, and L. W. Seymour, “Polymer-coated adenovirus Permits Efficient Retargeting and Evades Neutralising Antibodies,” Gene Therapy 8, no. 5 (2001): 341–348.

[178] P. H. Kim, J. Kim, T. I. Kim, et al., “Bioreducible Polymer-conjugated Oncolytic adenovirus for Hepatoma-specific Therapy via Systemic Administration,” Biomaterials 32, no. 35 (2011): 9328–9342.

[179] J. Kim, H. Y. Nam, T. I. Kim, et al., “Active Targeting of RGD-conjugated Bioreducible Polymer for Delivery of Oncolytic adenovirus Expressing shRNA Against IL-8 mRNA,” Biomaterials 32, no. 22 (2011): 5158–5166.

[180] Y. Liang, B. Wang, Q. Chen, et al., “Systemic Delivery of Glycosylated-PEG-masked Oncolytic Virus Enhances Targeting of Antitumor Immuno-virotherapy and Modulates T and NK Cell Infiltration,” Theranostics 13, no. 15 (2023): 5452–5468.

[181] C. Hill, M. Grundy, L. Bau, et al., “Polymer Stealthing and Mucin-1 Retargeting for Enhanced Pharmacokinetics of an Oncolytic Vaccinia Virus,” Mol Ther Oncolytics 21 (2021): 47–61.

[182] W. S. Lee, S. J. Lee, H. J. Lee, et al., “Oral Reovirus Reshapes the Gut Microbiome and Enhances Antitumor Immunity in Colon Cancer,” Nature Communications 15, no. 1 (2024): 9092.

[183] T. J. Harryvan, M. Golo, N. Dam, et al., “Gastrointestinal Cancer-associated Fibroblasts Expressing Junctional Adhesion Molecule-A Are Amenable to Infection by Oncolytic Reovirus,” Cancer Gene Therapy 29, no. 12 (2022): 1918–1929.

[184] P. Gong, F. Wang, Y. Hua, J. Ying, J. Chen, and Y. Qiao, “Collagenase-mediated Extracellular Matrix Targeting for Enhanced Drug Penetration and Therapeutic Efficacy in Nanoscale Delivery Systems for Cancer Therapy,” J Nanobiotechnology 23, no. 1 (2025): 733.

[185] T. Liao, X. Chen, F. Qiu, et al., “Regulation of Cancer-associated Fibroblasts for Enhanced Cancer Immunotherapy Using Advanced Functional Nanomedicines: An Updated Review,” J Nanobiotechnology 23, no. 1 (2025): 166.

[186] H. Jia, X. Chen, L. Zhang, and M. Chen, “Cancer Associated Fibroblasts in Cancer Development and Therapy,” Journal of hematology & oncology 18, no. 1 (2025): 36.

[187] Z. Zhang, Y. Yu, Z. Zhang, et al., “Cancer-associated Fibroblasts-derived CXCL12 Enhances Immune Escape of Bladder Cancer Through Inhibiting P62-mediated Autophagic Degradation of PDL1,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 316.

[188] J. de Sostoa, C. A. Fajardo, R. Moreno, M. D. Ramos, M. Farrera-Sal, and R. Alemany, “Targeting the Tumor Stroma With an Oncolytic adenovirus Secreting a Fibroblast Activation Protein-targeted Bispecific T-cell Engager,” Journal for ImmunoTherapy of Cancer 7, no. 1 (2019): 19.

[189] J. Kiyokawa, Y. Kawamura, S. M. Ghouse, et al., “Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma,” Clinical Cancer Research 27, no. 3 (2021): 889–902.

[190] G. F. Soko, B. K. Kosgei, S. S. Meena, et al., “Extracellular Matrix Re-normalization to Improve Cold Tumor Penetration by Oncolytic Viruses,” Frontiers in immunology 15 (2024): 1535647.

[191] J. L. Chitty, M. Yam, L. Perryman, et al., “A First-in-class Pan-lysyl Oxidase Inhibitor Impairs Stromal Remodeling and Enhances Gemcitabine Response and Survival in Pancreatic Cancer,” Nat Cancer 4, no. 9 (2023): 1326–1344.

[192] Y. Choi and K. Jung, “Normalization of the Tumor Microenvironment by Harnessing Vascular and Immune Modulation to Achieve Enhanced Cancer Therapy,” Experimental & Molecular Medicine 55, no. 11 (2023): 2308–2319.

[193] K. Matuszewska, L. A. Santry, J. P. van Vloten, et al., “Combining Vascular Normalization With an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer,” Clinical Cancer Research 25, no. 5 (2019): 1624–1638.

[194] Y. Bykov and D. Zamarin, “Virus, Vessel, Victory: A Novel Approach to Tumor Killing,” Clinical Cancer Research 25, no. 5 (2019): 1446–1448.

[195] Y. Boucher, A. S. Kumar, J. M. Posada, et al., “Bevacizumab Improves Tumor Infiltration of Mature Dendritic Cells and Effector T-cells in Triple-negative Breast Cancer Patients,” NPJ Precis Oncol 5, no. 1 (2021): 62.

[196] P. K. Wan, R. A. Fernandes, and L. W. Seymour, “Oncolytic Viruses and Antibodies: Are They More Successful When Delivered Separately or When Engineered as a Single Agent?,” Journal for ImmunoTherapy of Cancer 11, no. 8 (2023): e006518.

[197] F. Mpekris, M. Panagi, A. Charalambous, C. Voutouri, and T. Stylianopoulos, “Modulating Cancer Mechanopathology to Restore Vascular Function and Enhance Immunotherapy,” Cell Rep Med 5, no. 7 (2024): 101626.

[198] Z. Chen, F. Han, Y. Du, H. Shi, and W. Zhou, “Hypoxic Microenvironment in Cancer: Molecular Mechanisms and Therapeutic Interventions,” Signal Transduct Target Ther 8, no. 1 (2023): 70.

[199] S. Shayan, A. Arashkia, and K. Azadmanesh, “Modifying Oncolytic Virotherapy to Overcome the Barrier of the Hypoxic Tumor Microenvironment. Where Do We Stand?,” Cancer cell international 22, no. 1 (2022): 370.

[200] Y. Wang, G. Zhang, Q. Meng, et al., “Precise Tumor Immune Rewiring via Synthetic CRISPRa Circuits Gated by Concurrent Gain/Loss of Transcription Factors,” Nature Communications 13, no. 1 (2022): 1454.

[201] Y. Chen, J. Wang, Y. Huang, et al., “An Oncolytic System Produces Oxygen Selectively in Pancreatic Tumor Cells to Alleviate Hypoxia and Improve Immune Activation,” Pharmacological Research 199 (2024): 107053.

[202] M. Cabeza-Cabrerizo, A. Cardoso, C. M. Minutti, M. Pereira da Costa, and C. Reis e Sousa, “Dendritic Cells Revisited,” Annual Review of Immunology 39 (2021): 131–166.

[203] U. R. M. Reuter, R. Oettmeier, and U. Hobohm, “Safety of Therapeutic Fever Induction in Cancer Patients Using Approved PAMP Drugs,” Transl Oncol 11, no. 2 (2018): 330–337.

[204] J. H. Zheng, V. H. Nguyen, S. N. Jiang, et al., “Two-step Enhanced Cancer Immunotherapy With Engineered Salmonella Typhimurium Secreting Heterologous Flagellin,” Science Translational Medicine 9, no. 376 (2017): eaak9537.

[205] B. E. Kennedy, M. Sadek, and S. A. Gujar, “Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy,” Molecular Therapy 28, no. 6 (2020): 1417–1421.

[206] Y. Qian, A. Galan-Cobo, I. Guijarro, et al., “MCT4-dependent Lactate Secretion Suppresses Antitumor Immunity in LKB1-deficient Lung Adenocarcinoma,” Cancer Cell 41, no. 7 (2023): 1363–1380.e7.

[207] S. Verma, S. Budhu, I. Serganova, et al., “Pharmacologic LDH Inhibition Redirects Intratumoral Glucose Uptake and Improves Antitumor Immunity in Solid Tumor Models,” Journal of Clinical Investigation 134, no. 17 (2024): e177606.

[208] R. M. Peralta, B. Xie, K. Lontos, et al., “Dysfunction of Exhausted T Cells Is Enforced by MCT11-mediated Lactate Metabolism,” Nature Immunology 25, no. 12 (2024): 2297–2307.

[209] M. C. Merlano, N. Denaro, D. Galizia, et al., “How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review,” Biomedicines 10, no. 8 (2022): 1822.

[210] S. Liu, W. Wang, S. Hu, et al., “Radiotherapy Remodels the Tumor Microenvironment for Enhancing Immunotherapeutic Sensitivity,” Cell death & disease 14, no. 10 (2023): 679.

[211] H. Soliman, D. Hogue, H. Han, et al., “Oncolytic T-VEC Virotherapy plus Neoadjuvant Chemotherapy in Nonmetastatic Triple-negative Breast Cancer: A Phase 2 Trial,” Nature Medicine 29, no. 2 (2023): 450–457.

[212] A. S. Clark, F. Zhao, P. Klein, et al., “A Phase II Randomized Study of Paclitaxel Alone or Combined With Pelareorep With or Without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study,” Clinical Cancer Research 31, no. 13 (2025): 2655–2662.

[213] B. L. Musher, E. K. Rowinsky, B. G. Smaglo, et al., “LOAd703, an Oncolytic Virus-based Immunostimulatory Gene Therapy, Combined With Chemotherapy for Unresectable or Metastatic Pancreatic Cancer (LOKON001): Results From Arm 1 of a Non-randomised, Single-centre, Phase 1/2 Study,” The Lancet Oncology 25, no. 4 (2024): 488–500.

[214] R. Garcia-Carbonero, M. Bazan-Peregrino, M. Gil-Martín, et al., “Phase I, Multicenter, Open-label Study of Intravenous VCN-01 Oncolytic adenovirus With or Without Nab-paclitaxel plus Gemcitabine in Patients With Advanced Solid Tumors,” Journal for ImmunoTherapy of Cancer 10, no. 3 (2022): e003255.

[215] S. Wang, Y. Li, C. Xu, J. Dong, and J. Wei, “An Oncolytic Vaccinia Virus Encoding Hyaluronidase Reshapes the Extracellular Matrix to Enhance Cancer Chemotherapy and Immunotherapy,” Journal for ImmunoTherapy of Cancer 12, no. 3 (2024): e008431.

[216] M. Bazan-Peregrino, R. Garcia-Carbonero, B. Laquente, et al., “VCN-01 Disrupts Pancreatic Cancer Stroma and Exerts Antitumor Effects,” Journal for ImmunoTherapy of Cancer 9, no. 11 (2021): e003254.

[217] S. R. Jhawar, S. J. Wang, A. Thandoni, et al., “Combination Oncolytic Virus, Radiation Therapy, and Immune Checkpoint Inhibitor Treatment in Anti-PD-1-refractory Cancer,” Journal for ImmunoTherapy of Cancer 11, no. 7 (2023): e006780.

[218] K. J. Harrington, E. M. Karapanagiotou, V. Roulstone, et al., “Two-stage Phase I Dose-escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients With Advanced Cancers,” Clinical Cancer Research 16, no. 11 (2010): 3067–3077.

[219] J. J. Wright, A. C. Powers, and D. B. Johnson, “Endocrine Toxicities of Immune Checkpoint Inhibitors,” Nature reviews Endocrinology 17, no. 7 (2021): 389–399.

[220] J. R. Hu, R. Florido, E. J. Lipson, et al., “Cardiovascular Toxicities Associated With Immune Checkpoint Inhibitors,” Cardiovascular Research 115, no. 5 (2019): 854–868.

[221] B. T. Fife and J. A. Bluestone, “Control of Peripheral T-cell Tolerance and Autoimmunity via the CTLA-4 and PD-1 Pathways,” Immunological Reviews 224 (2008): 166–182.

[222] F. Nassiri, V. Patil, L. S. Yefet, et al., “Oncolytic DNX-2401 Virotherapy plus Pembrolizumab in Recurrent Glioblastoma: A Phase 1/2 Trial,” Nature Medicine 29, no. 6 (2023): 1370–1378.

[223] A. N. Shoushtari, A. J. Olszanski, M. Nyakas, et al., “Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma,” Clinical Cancer Research 29, no. 1 (2023): 100–109.

[224] M. K. Wong, M. M. Milhem, J. J. Sacco, et al., “RP1 Combined with Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE),” Journal of Clinical Oncology 43, no. 33 (2025): 3589–3599.

[225] D. Mahalingam, G. A. Wilkinson, K. H. Eng, et al., “Pembrolizumab in Combination With the Oncolytic Virus Pelareorep and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma: A Phase Ib Study,” Clinical Cancer Research 26, no. 1 (2020): 71–81.

[226] T. Azad, R. Rezaei, R. Singaravelu, et al., “Synthetic Virology Approaches to Improve the Safety and Efficacy of Oncolytic Virus Therapies,” Nature Communications 14, no. 1 (2023): 3035.

[227] M. Nakatake, N. Kuwano, E. Kaitsurumaru, H. Kurosaki, and T. Nakamura, “Fusogenic Oncolytic Vaccinia Virus Enhances Systemic Antitumor Immune Response by Modulating the Tumor Microenvironment,” Molecular Therapy 29, no. 5 (2021): 1782–1793.

[228] Y. Wang, X. Pang, R. Li, et al., “Mesenchymal Stem Cells Carrying Viral Fusogenic Protein p14 to Treat Solid Tumors by Inducing Cell-Cell Fusion and Immune Activation,” Research (Wash D C) 8 (2025): 0594.

[229] F. Le Boeuf, S. Gebremeskel, and N. McMullen, “Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models,” Mol Ther Oncolytics 6 (2017): 80–89.

[230] K. Ottolino-Perry, J. S. Diallo, B. D. Lichty, J. C. Bell, and J. A. McCart, “Intelligent Design: Combination Therapy With Oncolytic Viruses,” Molecular Therapy 18, no. 2 (2010): 251–263.

[231] M. J. Webb, T. Sangsuwannukul, J. van Vloten, et al., “Expression of Tumor Antigens Within an Oncolytic Virus Enhances the Anti-tumor T Cell Response,” Nature Communications 15, no. 1 (2024): 5442.

[232] E. Ilett, T. Kottke, J. Thompson, et al., “Prime-boost Using Separate Oncolytic Viruses in Combination With Checkpoint Blockade Improves Anti-tumour Therapy,” Gene Therapy 24, no. 1 (2017): 21–30.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.